• June 3-6, 2024
  • San Diego Convention Center, California

Start-Up Stadium

Start-Up Stadium at BIO 2024

Start-Up Stadium is designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, strategic partners, and non-dilutive capital at the world’s largest biotechnology partnering event.

During the 2024 BIO International Convention select finalists from around the world will share a quick pitch showcasing new technologies and therapeutic solutions to a panel of investor judges, followed by live feedback.  Finalists will be eligible for a highly discounted registration rate to attend the 2024 BIO International Convention.  

 

start up stadium
 

Here's who you'll see at the Start-Up Stadium this year:

Loading
  1. AcroCyte Therapeutics is a cell-based precision medicine company. Our current focus lies in utilizing our core technology R3CE—rapid, reproducible, rare cell expansion— to assist clinical treatment and scientific research.
    Start-Up Stadium Session
    • Tools/Drug Development Support Tech
    5B
  2. AgenT is a French life sciences company on a mission to defeat Alzheimer's by targeting the silent phase.
    Start-Up Stadium Session
    • CNS/Neurological
    5B
  3. Aluda was founded to reexamine how fundamental cell processes are altered by disease, combining rational drug design with holistic objectives to make wider impact.
    Start-Up Stadium Session
    • Immunology
    5B
  4. We are addressing the need for tissue repair solutions, beginning with cornea.
    Start-Up Stadium Session
    • Ophthalmology
    5B
  5. Black Canyon Bio (BCB) is developing novel products for treating cancer using our proprietary Specific Neo-Antigen Peptides (SNAPTM) Technology platform.
    Start-Up Stadium Session
    • Oncology
    5B
  6. We are pioneering a novel approach by integrating proprietary synthetic biology methods and de novo protein designs with the power of generative AI to automate the discovery process and develop patient-tailored immune-mediated therapies at scale for Chronic and Age-Related diseases.
    Start-Up Stadium Session
    • Platform for Therapeutics
    5B
  7. CELLeBRAIN is an R&D biotechnology company specializing in the development of gene and cell therapy for the treatment of solid cancers, with a particular focus on glioblastoma multiforme (GBM).
    Start-Up Stadium Session
    • Oncology
    5B
  8. Cha Therapeutics seeks to realize the untapped potential of immune checkpoint inhibitors (ICIs).
    Start-Up Stadium Session
    • Oncology
    5B
  9. Coastar Therapeutics is a venture-backed biotech company based in San Diego, CA focused on next generation gene delivery technology.
    Start-Up Stadium Session
    • Cell and Gene Therapy and Genome Editing
    5B
  10. CytoArm focuses on untreatable diseases through a next generation T cell therapy, Armed-T cell.
    Start-Up Stadium Session
    • Oncology
    5B
  11. Endure Biotherapeutics (“Endure Bio”®) is developing engineered engraftable live biotherapeutics for metabolic diseases by genetically engineering human native bacteria to express therapeutic compounds.
    Start-Up Stadium Session
    • Platform for Therapeutics
    5B
  12. The mission of Everfront Biotech is to address unmet medical needs by developing orphan drugs to treat some of the world's deadliest diseases, including high-grade gliomas and pancreatic cancer.
    Start-Up Stadium Session
    • Oncology
    5B
  13. FELIQS is a clinical-ready stage company. The Company has a portfolio of two patent-protected drug product ophthalmology candidates.
    Start-Up Stadium Session
    • Ophthalmology
    5B
  14. Fzata (fzata.com) has solved the oral biologics problem with the BIoPYM platform.
    Start-Up Stadium Session
    • Platform for Therapeutics
    5B
  15. GelSana's novel polymers improve healing in impaired wounds, particularly in chronic wounds with high inflammation.
    Start-Up Stadium Session
    • Inflammation
    5B
  16. HBI is a private company focused on developing cutting-edge Microbiome-Based Therapeutics.
    Start-Up Stadium Session
    • Platform for Therapeutics
    5B
  17. ImmunoShield Therapeutics seeks to enable the high-throughput biomanufacturing of hydrogel-based regenerative medicine products and the application of allogeneic cell products in the absence of chronic systemic immunosuppression.
    Start-Up Stadium Session
    • Platform for Therapeutics
    5B
  18. Incircular's mission is to advance Biotech and Pharma applications by effective stabilization of proteins using INCYPRO, a cutting-edge chemical protein engineering technology.
    Start-Up Stadium Session
    • Tools/Drug Development Support Tech
    5B
  19. Isosterix is developing a differentiated small-molecule inhibitor of Kat6A, an epigenetic oncogene which is amplified and implicated in multiple tumor types, including breast cancer.
    Start-Up Stadium Session
    • Oncology
    5B
  20. Jaan biotherapeutics is a pre-investigational new drug application company developing treatments that target microRNAs to regenerate heart muscle withing the heart and treat heart disease, the largest cause of death of man.
    Start-Up Stadium Session
    • Cardiovascular
    5B
  21. KaloCyte is a pre-clinical biotech therapeutic startup company developing ErythroMer, a bioengineered artificial red blood cell (RBC) substitute that can be freeze-dried for long-term storage.
    Start-Up Stadium Session
    • Cardiovascular
    5B
  22. Keliomics is an emerging biotechnology company whose breakthrough platform for organ-scale biology preserves the full composition, structure, and function of primary human tissues.
    Start-Up Stadium Session
    • Tools/Drug Development Support Tech
    5B
  23. Leverna Therapeutics is a Boston-based preclinical RNA therapeutics company developing a portfolio of CNS-focused antisense oligonucleotide (ASO) programs.
    Start-Up Stadium Session
    • CNS/Neurological
    5B
  24. Biotech company with the goal to solve the antimicrobial resistance pandemic for anyone, anything, anywhere.
    Start-Up Stadium Session
    • Infectious Disease and Vaccines
    5B
  25. Longieva has been developing novel therapeutics for validated targets for CNS disorders with utility in neurodegeneration (such as Alzheimer's and Parkinson's) and addictive disorders.
    Start-Up Stadium Session
    • CNS/Neurological
    5B
  26. Mabswitch Inc, is a leading biotechnology firm specializing in the development of regulatable immunotherapies based on the groundbreaking invention of affinity switches for antibodies.
    Start-Up Stadium Session
    • Oncology
    5B
  27. Matrubials Inc. is developing milk-inspired therapeutics to address infectious diseases.
    Start-Up Stadium Session
    • Infectious Disease and Vaccines
    5B
  28. Merlin has a pre-clinical mRNA-delivered immune activator with strong IP with in-vivo and human epi survival data in both pediatric ($100M PRV) and $2B adult markets.
    Start-Up Stadium Session
    • Oncology
    5B
  29. Founded in 2018 and headquartered in Derio (Bizkaia), Mikrobiomik is a bio-pharmaceutical company created to conduct research, develop and manufacture of medicines based on the human microbiome.
    Start-Up Stadium Session
    • Platform for Therapeutics
    5B
  30. Minutia is developing a regenerative medicine platform that improves safety and success outcomes of transplanted cells, our first therapy is a functional cure for Type 1 and Insulin Dependent Type 2 Diabetes with a simple outpatient procedure.
    Start-Up Stadium Session
    • Cell and Gene Therapy and Genome Editing
    5B
  31. NemaGen Discoveries is a New Jersey-based biotechnology company that is advancing therapies for patients suffering from allergic disorders and pulmonary fibrosis.
    Start-Up Stadium Session
    • Immunology
    5B
  32. Neuroene is developing mitochondrial-protective small molecules for epilepsy, Parkinson's and mitochondrial diseases.
    Start-Up Stadium Session
    • CNS/Neurological
    5B
  33. Neuronascent Inc. discovers and develops novel neuron regenerative therapies for neurodegenerative and rare pediatric neurological diseases.
    Start-Up Stadium Session
    • CNS/Neurological
    5B
  34. Oniria Therapeutics aims to revolutionize cancer treatment by bringing to market the first-in-class drug ONR-001, designed for solid and liquid aggressive tumors unresponsive to current treatments, paving the way for novel therapeutic combinations or standalone treatments.
    Start-Up Stadium Session
    • Oncology
    5B
  35. Orakl Oncology stands at the forefront of the techbio landscape, pioneering the use of patient tumor avatars to meticulously accelerate and de-risk drug development.
    Start-Up Stadium Session
    • Oncology
    5B
  36. Origami Therapeutics is developing curative therapies that target and degrade disease-related proteins.
    Start-Up Stadium Session
    • CNS/Neurological
    5B
  37. Orlia provides optimization tools to maximize yield and improve cell health and viability in bioreactors and fermenters.
    Start-Up Stadium Session
    • Tools/Drug Development Support Tech
    5B
  38. Papillon Therapeutics is a biotechnology company advancing genetic medicines for life threatening conditions with neurologic disease.
    Start-Up Stadium Session
    • CNS/Neurological
    5B
  39. PHIOGEN is a spin-off from Baylor College of Medicine and was born out of innovation from the globally renowned team at TAILOR Labs, one of the US's only bacteriophage therapy centers, now being commercialized to combat the AMR infection crisis.
    Start-Up Stadium Session
    • Infectious Disease and Vaccines
    5B
  40. SiNON has developed a patented tunable carbon nanoparticle that acts as a ‘Trojan horse' drug delivery platform that allows drugs to cross the blood brain barrier to treat many different neurological diseases.
    Start-Up Stadium Session
    • CNS/Neurological
    5B
  41. SLAM Bio is a preclinical stage biotech company developing a platform of antibodies and antibody drug conjugates (ADCs) against signaling lymphocytic activation molecule (SLAM) protein family.
    Start-Up Stadium Session
    • Oncology
    5B
  42. Suntec has a proprietary MINC (Multi-target Immune-modulation Nanocomplex) technology platform to develop highly effective and safe immunotherapies.
    Start-Up Stadium Session
    • Platform for Therapeutics
    5B
  43. Synergy Therapeutics Inc. has discovered and developed a novel and disruptive way to potently upregulate p53, the "guardian of the genome", in both wildtype and mutant cancer cells.
    Start-Up Stadium Session
    • Oncology
    5B
  44. Tachmed develops revolutionary, proprietary technologies designed to detect chronic and infectious diseases.
    Start-Up Stadium Session
    • Diagnostics and Personalized Medicine
    5B
  45. Trust Bio-sonics Inc. is a Taiwan based pharmaceutic company (Private) and a world leader in microsphere technologies for contrast-enhanced ultrasound imaging and ultrasound-mediated drug delivery technologies.
    Start-Up Stadium Session
    • Platform for Therapeutics
    5B
  46. VoxCell is creating human-like vascularized tissue models as a screening platform in drug development; by combining Canada's first high-resolution 3D bioprinter, VoxCell's proprietary universal bioinks and VoxCell's vascularization software.
    Start-Up Stadium Session
    • Tools/Drug Development Support Tech
    5B
  47. Vyro is a worldwide pioneer in the development of therapies and drug-delivery viral vectors based on Zika.
    Start-Up Stadium Session
    • Platform for Therapeutics
    5B

New this year!

This year will also feature evaluation of the presentations from seed-stage company finalists (less than $1M raised) separate from emerging company finalists (more than $1M but less than $10M raised to date). with a winner identified for each category. Past prizes have included 'fast-track' admission review to incubator programs at the  Illumina Accelerator and  The Innovation Space, as well as complimentary, one-year memberships in the Biotechnology Innovation Organization with access to the cost-savings programs of  BIO Business Solutions.  

Need Advice on Your Pitch Deck?

Download our pitch presentation guide for additional insight and advice on building a stellar submission,

Download

Congratulations to our 2023 Seed-Stage and Emerging Winners

2023 SEED-STAGE START-UP WINNER

PriZm Therapeutics

Chandler, Arizona

Learn More

2023 EMERGING START-UP WIINNER

Paradox Immunotherapeutics

Learn more

2023 Seed-Stage Finalists

Company Website

48Hour Discovery
Azora Therapeutics
Clinials
Cyta Therapeutics
Delymer Therapeutics
Guardian Bio
ImunoTera
Mirscience Therapeutics
Moleculex co., ltd.
NCMN Bio
PriZm Therapeutics [Winner]
ReNewVax Ltd
RT MicroDx
Saros Therapeutics
StemSight
T-E Meds, Inc.
VaxSyna, Inc.

Main Therapeutic Focus

Platform for Therapeutics
Immunology
Tools/Drug Development Support Tech
Metabolic Diseases
Gene/Cell Therapy
Oncology
Immunology
Regenerative Medicine
Inflammation
Platform for Therapeutics
Orphan/Rare Diseases
Vaccines
Diagnostics
Oncology
Regenerative Medicine
Oncology
Vaccines

Company Location

Canada
United States (California)
Australia
United States (Massachusetts)
United States (Massachusetts)
United States (Massachusetts)
Brazil
Brazil
Taiwan
United States (Virginia)
United States (Arizona)
United Kingdom
United States (Massachusetts)
United States (Illinois)
Finland
Taiwan
United States (New Hampshire

2023 Emerging Start-Up Finalists

AnHorn Medicines Co., Ltd.
Anticipate Bioscience
ARCE Therapeutics
Ardan Pharma
ARIZ Precision Medicine
Asgard Therapeutics
AyuVis Research, Inc.
CorriXR Therapeutics
ElectraTect, Inc.
Enquyst Technologies Inc
FAKnostics,LLC
FELIQS Corporation
Genius Holdings Co., Ltd
Gilboa Therapeutics
Grannus Therapeutics, Inc.
Immuto Scientific
LASE Innovation
Limax Biosciences, Inc.
March Biosciences
MC Sciences
MelliCell, Inc
Neuroene Therapeutics
OmniCyte
pacDNA Therapeutics
Paradox Immunotherapeutics  [Winner]
Promakhos Therapeutics
Reference Medicine
Reglagene
Swaza
Zehna Therapeutics Inc

Platform for Therapeutics
Oncology
Oncology
Oncology
Oncology
Oncology
Immunology
Oncology
Diagnostics
Tools/Drug Development Support Tech
Oncology
Ophthalmology
Respiratory
Oncology
Oncology
Platform for Therapeutics
Tools/Drug Development Support Tech
Inflammation
Oncology
Platform for Therapeutics
Metabolic Diseases
CNS/Neurological
Oncology
Platform for Therapeutics
Immunology
Inflammation
Diagnostics
CNS/Neurological
Respiratory
Metabolic Diseases

Taiwan
United States (Arizona)
Taiwan
Argentina
United States (California)
Sweden
United States (Texas)
United States (Delaware)
United States (Arizona)
United States (Massachusetts)
United States (Arizona)
Japan
Taiwan
Israel
United States (Indiana)
United States (Wisconsin)
United States (Massachusetts)
United States (Massachusetts)
United States (Texas)
Germany
United States (Massachusetts)
United States (District Of Columbia)
United States (Connecticut)
United States (Massachusetts)
Canada
United States (Massachusetts)
United States (Arizona)
United States (Arizona)
United States (California)
United States (Ohio)

BIO Thanks the 2023 Participating BIO Start-Up Stadium Judges:

  • Christopher Aleong, Chief Business Officer, Lumosa Therapeutics; Managing Director, BioEngine Capital
  • Gad Berdugo, Managing Partner, Explorium Capital LLC
  • David H. Crean, PhD, Managing General Partner, Cardiff Advisory LLC
  • Kevin Emesiani, PharmD, Senior Associate, Medical Excellence Capital, LLC
  • Bettina Ernst, Director, BERNINA BioInvest
  • Gail Christine Gannon, CEO of Ensanté & Director, Neurotech Collider Lab, UC Berkeley
  • Lu Han, PhD, Partner, Lumira Ventures
  • Mike Huckman, Global Practice Leader, Executive Communications, Real Chemistry
  • Scott M. Kahn, PhD, Founder, Alykomed Global Solutions LLC
  • George MacDougall, Director, Investor Relations & Corporate Communications, Gritstone bio, Inc.
  • Stephanie Marrus, Managing Director of Entrepreneurship, Innovation Ventures, UCSF
  • Anton Neschadim, PhD, Senior Advisor, GreenSky Capital
  • Vinit Nijhawan, Managing Director, MassVentures
  • Younes Ouahid, PhD, Partner, Facultas Partners
  • William D. Provine, PhD, President & CEO, Innovation Space
  • Ryan Roller, Managing Director, Life Science & Healthcare, HSBC
  • Lesley Stolz, PhD, VP, Early Innovation Partnering, Johnson & Johnson Innovation
  • Kitty Wu, PhD, VP, Head of Business Development and Strategy, Fosun Pharma USA
  • Samuel Wu, MD, PhD, Venture Partner, 7G BioVentures
  • John Zhu, PhD, Founder and President, Mayewell Capital

white squarewhite

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS